- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/48 - Nerve growth factor [NGF]
Patent holdings for IPC class C07K 14/48
Total number of patents in this class: 205
10-year publication summary
|
10
|
18
|
15
|
16
|
23
|
14
|
12
|
10
|
26
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Staidson (Beijing) Biopharmaceuticals Co., Ltd. | 70 |
11 |
| JCR Pharmaceuticals Co., Ltd. | 227 |
9 |
| MedImmune Limited | 622 |
9 |
| Levicept Ltd | 28 |
8 |
| Chiesi Farmaceutici S.p.A. | 963 |
5 |
| Wacker Chemie AG | 2106 |
5 |
| Xintrum Pharmaceuticals, Ltd | 14 |
5 |
| Wyvern Pharmaceuticals Inc. | 98 |
5 |
| The Regents of the University of California | 20473 |
4 |
| Centre National de La Recherche Scientifique | 10841 |
4 |
| The Board of Trustees of the Leland Stanford Junior University | 6605 |
4 |
| Quethera Limited | 8 |
4 |
| In3bio Ltd. | 23 |
4 |
| The Cleveland Clinic Foundation | 1583 |
3 |
| Manzanita Pharmaceuticals, Inc. | 9 |
3 |
| HOBA Therapeutics ApS | 18 |
3 |
| Stealth Biotherapeutics Inc. | 181 |
3 |
| Human Cell Co. | 3 |
3 |
| Hoffmann-La Roche Inc. | 3646 |
2 |
| Tsinghua University | 6091 |
2 |
| Other owners | 109 |